{"entity":{"id":"auron-therapeutics","kind":"company","name":"Auron Therapeutics","aka":[],"tldr":"Auron Therapeutics makes a tablet medicine, AUTX-703, that breaks down two proteins some cancers depend on to stay in an aggressive state. It is in an early trial for acute myeloid leukaemia and myelodysplastic syndrome that has come back or not responded to treatment.","summary":"Auron Therapeutics, based in Newton, Massachusetts, targets cell-state plasticity in cancer and inflammatory disease. Its AURIGIN platform combines a proprietary single-cell genomic database with AI and machine-learning tools to compare healthy and diseased cell states and to pick targets, models and biomarkers. The lead candidate AUTX-703 is a first-in-class oral degrader of KAT2A and KAT2B; the company names acute myeloid leukaemia, small cell lung cancer and neuroendocrine prostate cancer as its initial indications of interest. The FDA cleared its IND in early 2025 and granted Fast Track designation for relapsed or refractory AML in February 2025, and the company announced the first patient dosed in the phase 1 trial in advanced haematological malignancies on 30 May 2025. Its first registered cancer trial, NCT06846606, was posted on ClinicalTrials.gov in February 2025. In February 2025 it completed a USD 27 million Series B led by DCVC Bio, with Apollo Health Ventures, Arkin Bio Ventures, BrightEdge (the investment arm of the American Cancer Society), Casdin Capital, Franklin Berger, Mubadala Capital, Polaris Partners and Qiming Venture Partners USA.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://aurontx.com/"},{"label":"First patient dosed with AUTX-703, May 2025","url":"https://aurontx.com/news/auron-announces-first-patient-dosed-in-phase-1-clinical-trial-of-autx-703-in-advanced-hematologic-malignancies"},{"label":"ClinicalTrials.gov: phase 1 trial of AUTX-703 in relapsed or refractory AML and MDS (NCT06846606)","url":"https://clinicaltrials.gov/study/NCT06846606"}],"tags":[],"related":[],"cancers":["aml","mds","sclc","prostate-nepc"],"sections":["targeted-therapy","drug-discovery","ai-computation"],"technologies":["protac-degrader"],"targets":["kat2a","kat2b"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","The Series B lead, DCVC Bio, is not mapped to the corpus investor id dcvc because the two are not confirmed to be the same entity.","The corpus has no technology record specific to monovalent degraders, so the PROTACs and molecular glues tag is used for this degrader.","Company website and February 2025 release read on 29 October 2026."],"hq":"Newton, MA","country":"US","companyType":"biotech","website":"https://aurontx.com/","stage":"growth","investors":["acs-brightedge","casdin-capital","polaris-partners"],"funding":[{"round":"Series B","year":2025,"amountUsd":27000000,"source":"https://aurontx.com/news/auron-therapeutics-announces-fda-clearance-to-initiate-clinical-development-of-autx-703-and-completion-of-series-b-financing","note":"Led by DCVC Bio."}]},"route":"/companies/auron-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"kat2a","kind":"target","name":"KAT2A","route":"/targets/kat2a/"},{"id":"kat2b","kind":"target","name":"KAT2B","route":"/targets/kat2b/"}],"company":[{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/"},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/"},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/"}]}}